

# Clinical SCIENCE

C O N T E N T S

## REVIEW

### **The dopaminergic system in hypertension**

C. Zeng, M. Zhang, L. D. Asico, G. M. Eisner and P. A. Jose

583–597

Published on the Internet 14 May 2007, doi:10.1042/CS20070018

## PAPERS

### **Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed Type 2 diabetes**

F. Song, W. Jia, Y. Yao, Y. Hu, L. Lei, J. Lin, X. Sun and L. Liu

599–606

Published as Immediate Publication 8 January 2007, doi:10.1042/CS20060323

### **A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart**

K. Nakamura, M. Sata, H. Iwata, Y. Sakai, Y. Hirata, K. Kugiyama and R. Nagai

607–616

Published as Immediate Publication 31 January 2007, doi:10.1042/CS20060301

### **The lipoprotein lipase gene serine 447 stop variant influences hypertension-induced left ventricular hypertrophy and risk of coronary heart disease**

P. J. Talmud, D. M. Flavell, K. Alfakih, J. A. Cooper, A. J. Balmforth, M. Sivananthan, H. E. Montgomery, A. S. Hall and S. E. Humphries

617–624

Published as Immediate Publication 12 February 2007, doi:10.1042/CS20060344

## CORRECTION

### **Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome**

G. F. Watts, J. Ji, D. C. Chan, E. M. M. Ooi, A. G. Johnson, K.-A Rye and P. H. R. Barrett

(vol. 111, pp. 193–199, 2006)

625

Published on the Internet 14 May 2007